Coronary stents are China's first national high-value medical consumables collection procurement varieties, the first procurement cycle will soon expire. Today (29th), the next cycle of successive procurement work in Changzhou, Jiangsu Province was launched.
Coronary stent collectively procured successive procurement today, the process is simplified rules optimization
9:00 a.m., the filing enterprise began to submit the declaration materials, after the notary audit, the conference staff announced the enterprise declaration information. The state organization coronary stent band purchasing agreement expiration of successive procurement declaration *** there are 3696 medical institutions to participate in the amount of reporting, compared with the first set of procurement increased by 1288, medical institutions *** fill in the demand for 1.865 million.
A foreign-funded enterprise on behalf of Hu Jun: Because we as a foreign-funded enterprise to speak, the Chinese market is very important, so we will certainly, as always, to ensure that such a continuous increase in the service and supply work. After the band purchasing, the overall supply is actually increased significantly, at the same time, because of the price down, the people also really get some real benefits. I think it should be a very good result for both the companies and for the government and the people.
Yu Suhua, a representative of a domestic enterprise: In terms of actual results, after the band purchasing, people worried in advance about a sharp rise or sharp decline in the volume of surgery did not happen, the volume of surgery each year and the past five years basically to maintain a certain probability.
The successive procurement through the gradient allocation of the agreed procurement volume, to promote full competition among enterprises, to give full play to the effect of collective procurement "volume and price linkage, volume for price", and to guide enterprises to reasonably reduce prices in order to obtain more agreed procurement volume.
At the same time, the succession of procurement also provides that the unsuccessful products and new products, as long as the acceptance of the highest effective declared price, you can participate in the next agreement period, without the need to carry out the work of succession, greatly simplifies the process of succession, but also gives the unsuccessful products a full opportunity.
Gu Hai, director of the Center for Health Policy and Management Studies at Nanjing University:
They did not participate in the bidding before, and if other enterprises want to vote, as long as they meet the conditions, it can also participate in the bidding, so in this case, there are more unsuccessful enterprises and unsuccessful varieties and come in, so that this is the same as the increase in the supply. Both in terms of the amount of varieties and the number of enterprises have increased.
Medical institutions have used 1.69 million sets of selected coronary stents,saving more than 17.9 billion yuan
The first procurement cycle of coronary stents is two years, from January 1, 2021 officially landed, and patients around the world with high quality and inexpensive pharmaceutical products. Currently, the selected varieties with reduced prices have reached 1.69 million sets in clinical use, significantly reducing the burden of patients' medical care.
November 27, Jiangsu Changzhou, 40-year-old citizen Liu Yefeng due to chest tightness, was sent to Changzhou First People's Hospital emergency treatment, the doctor examined for acute myocardial infarction. Immediately after the doctor for the patient to carry out interventional surgery, implanted two coronary stents. After the operation, the patient turned to safety, and when he heard a coronary stent only 590 yuan, Liu Yefeng surprised.
Patient Liu Yefeng: Reduce the burden of us to see the doctor, save a large portion of the cost, this is a good policy of the country, to our people are universal benefit.
Coronary stents as a national organization of high-value medical supplies centralized volume purchasing "the first single", the selected varieties of the average price of about 700 yuan, an average reduction of 93%. Related products in January 2021 landing. During the first agreement period, medical institutions*** used 1.69 million sets of the selected coronary stents, reaching 1.6 times the annual agreement procurement volume, saving the country more than 17.9 billion yuan. The affordability of percutaneous coronary intervention (PCI) procedures for patients has been greatly improved, and according to relevant data, the volume of PCI procedures in China in 2021 will increase by more than 40% compared with 2020, giving full play to the effectiveness of the collection and procurement, and effectively reducing the burden on the public.
Yang Xiaoyu, Chief Physician of the Department of Cardiovascular Medicine at the First People's Hospital of Changzhou City, Jiangsu Province: We now have more than 100 cases of patients needing coronary intervention every month, and all of these patients are using collectively procured stents, and we have communicated with the suppliers beforehand to allow them to equip with different types of stents with multiple brands to choose from, so that the patients' clinical needs can be met. We have also communicated with the suppliers in advance so that they can equip different types of stents with several brands to choose from, which can meet the patients' clinical needs.
This time, more medical institutions participated in the procurement of stents, and 3,696 medical institutions participated in the procurement of stents, an increase of 1,288 compared to the first batch of stents, and 1,865,000 stents were filled in, 1.7 times more than the first batch of stents, reflecting a high degree of acceptance of the policy of stents by the medical institutions.
Successive procurement at the end of the period to reduce the cost of enterprises to stabilize the price level
With the deepening of the collection, there will be more and more collection of products will face the expiration of the procurement cycle of the situation, the collection of the expiration of the succession of work how to carry out the work of the national collection of coronary stent of the successive procurement will also be the renewal of the contract of the other collection of products will also provide a reference.
Since the establishment of the National Health Insurance Bureau, the national level has carried out seven batches of collection and procurement of drugs, and three batches of collection and procurement of high-value medical consumables such as coronary stents and orthopedics. Localities have also carried out extensive provincial and regional alliance collection, and the selected products have significantly reduced the burden of patients' medical treatment. With the local actively promote the medical consumables centralized band purchasing, everywhere one after another facing the product succession problem.
Currently, the state has not yet issued a special policy document for the continuation of the national organization of medical consumable centralized banded purchasing agreement after the expiration of the period, the state unified organization to carry out the continuation of the work of the coronary artery stent to improve administrative efficiency, as far as possible to eliminate the emergence of the local continuation of the non-standardized, non-uniform situation, to reduce the cost of the enterprises around the bidding process, to maximize the stabilization of the price level, coordination of price differences between localities, to ensure that localities are at the same price level. The price level can be stabilized to the greatest extent possible, coordinate the price differences between localities, ensure that all localities are at the same price level, and provide reference and reference for the development of the subsequent succession work.